Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
about
Melanoma: from melanocyte to genetic alterations and clinical optionsThe RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerTargeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitorsOptimal management of metastatic melanoma: current strategies and future directionsMelanoma: from mutations to medicineA Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanomaFunctional specialization in proline biosynthesis of melanomaIntegrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implicationsEnhancing the evaluation of PI3K inhibitors through 3D melanoma models.KGF Promotes Paracrine Activation of the SCF/c-KIT Axis from Human Keratinocytes to Melanoma Cells.GAB2 amplifications refine molecular classification of melanoma.Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal typeRecent advances on skin-resident stem/progenitor cell functions in skin regeneration, aging and cancers and novel anti-aging and cancer therapies.Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model.Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.MicroRNA in Melanoma.Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect.The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidenceNovel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomasThe current state of targeted therapy in melanoma: this time it's personalTargeting the RAS pathway in melanoma.MEK inhibition affects STAT3 signaling and invasion in human melanoma cell linesIn vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.Small molecules and targeted therapies in distant metastatic disease.Melanoma biomarkers: current status and utility in diagnosis, prognosis, and response to therapy.Mutation-driven drug development in melanoma.A new era: melanoma genetics and therapeutics.Receptor tyrosine kinases and their activation in melanoma.The future of targeted therapy approaches in melanoma.DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma.Increased levels of DUSP6 phosphatase stimulate tumourigenesis in a molecularly distinct melanoma subtype.Quantitative comparison of the spreading and invasion of radial growth phase and metastatic melanoma cells in a three-dimensional human skin equivalent model.Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanomaThe MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma.Sinonasal mucosal melanoma: Molecular profile and therapeutic implications from a series of 32 cases.KIT genetic alterations in anorectal melanomas.
P2860
Q54581163-18930233-DB8B-4110-96E1-7C8CD4EAA737Q54603178-BC512409-F743-44C8-8787-A775D7855D2DQ54994157-41667D28-E8F2-4226-910D-6BCC7785C39AQ54994164-6ADA301C-1569-4F81-8305-A861DC802FFBQ54994167-2EB13B13-D32E-4D31-AF51-3BD3601AA557Q54994168-669F9E08-7832-4249-81C2-78C547367A80Q54994170-8A3CAE2E-A357-49E3-81AB-DA6CFAB0B598Q54994172-B4B90499-2FA0-4D8F-A70D-B2E8C163C6FBQ54994173-217E6828-1538-4539-80B0-3542DAFF1BADQ54994187-0EA8BEB4-A391-455C-ADE8-39804E2B9D34Q54994193-4DD1651F-7A2C-4B8B-8223-AED27297944AQ54994197-BBDCA655-CBDF-45A1-9E77-76D4E6EEEFCDQ54994215-59F27778-4EA8-4F05-AC49-A8C9CEFBC2E1Q54994223-D7BBA943-A9E3-49C7-ADF5-C5B626997C4FQ54994241-6713C1D6-B8FC-48FB-8991-91A8359CEAE6Q54994244-6B773FF6-C626-43D4-B948-FD6B74E2B105Q54994246-C202A474-4C78-485E-AC88-AD9CE55D0D9CQ54994256-CF034B1F-0798-4DF0-A9F8-971265E14515Q54994301-108E6001-E448-4EB1-888D-3FD991E40DF1Q54994306-1E4C1EC7-439D-4BCD-8FB3-A9ED78D90E4BQ54994308-55448310-9DA8-454B-A060-9BC4CA70F1F7Q54994311-7525B267-38B5-4310-81C9-28399C88FF90Q54994312-17E42CC1-3C4A-40E6-AB7F-72C7DC35912FQ54994319-3698DE12-3286-441A-A240-2F553AF99520Q54994326-4035CA17-C2DD-4894-97B4-977741657AF3Q54994333-2E1C073C-8DC8-4562-A2BE-96B2518B8274Q54994340-B7630FF4-74C1-4F3D-84C3-2C3535F9028CQ54994345-90F2B536-87FD-41D6-B70E-45A85B797DFFQ54994346-5A1097DB-03BE-48D8-BDD4-455014C26868Q54994348-84346F2C-06E9-4954-BB49-B9D8F4FC9929
P1343
Q21284811-53CD0ADC-0B17-4DB2-BA7A-6C1B1A3A5753Q21629049-E8273506-760B-49AF-BC3D-9B06458EB470Q26827580-211A2E45-7389-4FAF-ABCD-A6DB5F25FEF9Q26997338-7728DB46-73E5-4140-B7CC-A8C727650736Q27024061-EEB9D80C-90CA-47A3-AA85-BB2D8270F21EQ27851611-5F5843D9-C1CF-4009-8809-8C03FB713832Q28118829-F18DB404-5D88-49E4-8997-006B3A960700Q28474843-3DA38B6A-BC29-4372-9E99-EBD4E152E5C5Q30746265-A018BF46-C726-4E21-935F-FA35557F88EEQ33760584-A2C7444F-4C30-4578-B63A-566A939E14A4Q33883923-32DA79CB-AC7A-4517-8067-DDE3D53CD92DQ33995919-242BAE21-2E33-46EE-990A-E0833153A693Q34044908-822F778D-E034-451C-A6C0-EC43CE378FA8Q34633885-CA4C81B7-8CC7-4918-9369-A9DF8A7F5E6EQ34761998-6F2CC241-25FD-442D-B6B9-A86BC7B44AB1Q34986222-3203158F-3535-4395-895E-473025DF25DCQ35605096-15C565EC-BEC7-4609-8E7B-6CD0850D7A73Q35810176-EFFC37C7-16AC-4AF9-852F-EB28DC86B93EQ35845352-C6B98015-E6A9-44DA-83F6-DF85A014D0C1Q35878248-16D995C8-F131-4441-B56B-82012CC5F7F1Q37137004-CA754A27-E858-46E8-9744-0281AC8812C0Q37161421-F49BD7EB-CECE-4905-A3C8-B7148A4B6CD4Q37202242-2F532CB9-2DE4-4079-92CA-E0D6840E61B7Q37480713-24DE0498-BDC6-407A-A9E7-67CD3955C4B6Q37555793-36B3335B-5331-4065-B982-FFA0CE38F3B5Q37605787-9043A9C5-CA3D-4AAE-BEC3-64AE7467BAE8Q37733450-984C7833-606B-4757-A33D-0121189B4E6BQ37815139-D71C65A5-6D7B-47D3-B21D-08F321865D36Q37841746-EED1A68D-0332-4293-9F3C-DE61CF299468Q38088812-265CF28B-7C7B-4AFD-95A1-4793163B22E4Q38120311-76DFE39C-EF65-4FB9-B1A7-587779A8101DQ39428048-5E195073-0CD2-4BAA-BBB7-FBF410717FBFQ41508982-DAB55B09-BE8F-4A3D-A80E-8ED6CEFCBE5FQ41910277-01AFEB27-042B-4BC7-B05B-ACDEC4610553Q44073293-B6F6CB88-95B6-4836-9972-18DAB83CD001Q54497681-B9D5459B-C081-46A9-86DB-14DEA9B8AD6EQ55070218-A11A9B32-5929-413F-AD0C-3F34F7AD98D1
P2860
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of a novel subg ...... ndent kinase-4 overexpression.
@en
Identification of a novel subg ...... ndent kinase-4 overexpression.
@nl
type
label
Identification of a novel subg ...... ndent kinase-4 overexpression.
@en
Identification of a novel subg ...... ndent kinase-4 overexpression.
@nl
prefLabel
Identification of a novel subg ...... ndent kinase-4 overexpression.
@en
Identification of a novel subg ...... ndent kinase-4 overexpression.
@nl
P2093
P2860
P4510
P50
P1433
P1476
Identification of a novel subg ...... ndent kinase-4 overexpression.
@en
P2093
Alastair J King
Marcus Bosenberg
Robin Edwards
Rooha Contractor
Thiennga K Nguyen
Viswanathan Muthusamy
P2860
P304
P356
10.1158/0008-5472.CAN-08-0235
P407
P577
2008-07-01T00:00:00Z